The value of prostate-specific antigen in the management of localized prostatic cancer.
Prostate-specific antigen has proven to be a new useful marker for the evaluation of men with prostatic cancer. In addition to its proven value for immunohistochemical staining and for the followup evaluation of men treated with hormonal therapy, the monoclonal immunoradiometric assay for PSA has proven to be a unique, sensitive, and specific marker for the followup evaluation of men who have undergone radical prostatectomy.
Walsh
P C
PC
Department of Urology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Oesterling
J E
JE
Epstein
J I
JI
Bruzek
D J
DJ
Rock
R C
RC
Chan
D W
DW
D000230:Adenocarcinoma / Q000276:immunology / Q000601:surgery; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen; D011468:Prostatectomy; D011470:Prostatic Hyperplasia / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000601:surgery
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen